Table 3 Patient characteristics
Characteristics | All patients, N = 739 | Survivors, N = 496 | Non-survivors, N = 243 | p |
|---|---|---|---|---|
At admission | ||||
- Age in years | 50 (36–63) | 46 (33–59) | 56 (43–72) | < 0.0001 |
- Sex female, n (%) | 271 (36.7) | 180 (36.3) | 91 (37.4) | 0.8214 |
- BMI in kg/m2 | 25 (22–28) | 24 (22–28) | 25 (22–29) | 0.0822 |
- Prehospital cardiac arrest (%) | 46 (6.2) | 11 (2.2) | 35 (14.4) | < 0.0001 |
- Prehospital GSC /15 | 15 (9–15) | 15 (13–15) | 14 (3–15) | < 0.0001 |
Comorbidities | ||||
- CKD, n (%) | 6 (0.8) | 2 (0.4) | 4 (1.6) | 0.0948 |
- Hypertension, n (%) | 141 (19.1) | 81 (16.3) | 60 (24.7) | 0.0088 |
- Diabetes mellitus, n (%) | 54 (7.3) | 28 (5.6) | 26 (10.7) | 0.0198 |
- CAOD, n (%) | 22 (3) | 7 (1.4) | 15 (6.2) | 0.0008 |
- CHF, n (%) | 33 (4.5) | 20 (4) | 13 (5.3) | 0.4858 |
Burn characteristic | ||||
- Burn, n (%) | 577 (78.1) | 357 (72) | 220 (90.5) | < 0.0001 |
- TBSA % | 20 (3–47) | 12 (0–30) | 50 (20–73) | < 0.0001 |
- 3rd degree TBSA % | 9 (0–30) | 2 (0–15) | 33 (10–58) | < 0.0001 |
SOFA at admission | 4 (1–7) | 2 (1–5) | 7 (3–10) | < 0.0001 |
MAP in mmHg | 86 (72–101) | 89 (76–102) | 80 (62–97) | < 0.0001 |
Vasopressor, n (%) | 226 (30.6) | 90 (18.1) | 136 (56) | < 0.0001 |
Hydroxocobalamin, n (%) | 386 (52.2) | 239 (48.2) | 147 (60.5) | 0.0021 |
HbCO % | 4 (2–10) | 4 (2–11) | 3 (2–7) | 0.0323 |
Biological data | ||||
- Plasmatic lactate in mmol/L | 3.0 (1.8–5.2) | 2.5 (1.4–3.8) | 4.8 (3–7.6) | < 0.0001 |
- Serum creatinine in μmol/L | 76 (59–101) | 71 (56–88) | 100 (72–123) | < 0.0001 |
- Maximal serum creatinine in μmol/L | 100 (73–162) | 84 (68–113) | 137 (102–212) | < 0.0001 |
Inhalation fibroscopic status (%) | 305 (41.3) | 175 (35.3) | 130 (53.5) | < 0.0001 |
- Grade 0, n | 1 (0.1) | 1 (0.2) | 0 (0) | 1 |
- Grade 1, n | 121 (16.4) | 90 (18.2) | 31 (12.8) | 0.0795 |
- Grade 2, n | 110 (14.9) | 67 (13.5) | 43 (17.7) | 0.1638 |
- Grade 3, n | 73 (9.9) | 17 (3.4) | 56 (23.1) | < 0.0001 |
- During ICU hospitalization | ||||
- AKI in the first week, n (%) | 288 (39) | 126 (25.4) | 162 (66.7) | < 0.0001 |
- Stage of AKI day 7 | ||||
- Stage 1, n (%) | 102 (13.8) | 63 (12.7) | 39 (16) | 0.2601 |
- Stage 2, n (%) | 39 (5.3) | 16 (3.2) | 23 (9.5) | 0.0007 |
- Stage 3, n (%) | 147 (19.9) | 47 (9.5) | 100 (41.2) | < 0.0001 |
- Severe AKI | 186 (25.2) | 63 (12.7) | 123 (50.6) | < 0.0001 |
- RRT at day 7, n (%) | 136 (18.8) | 44 (8.9) | 92 (37.9) | < 0.0001 |
- RRT in ICU, n (%) | 183 (24.8) | 58 (11.7) | 125 (51.4) | < 0.0001 |
- MAKE, n (%) | 313 (42.4) | 69 (13.9) | 243 (100) | < 0.0001 |
- Shock in ICU, n (%) | 402 (54.4) | 191 (38.5) | 211 (86.8) | < 0.0001 |
- Length of stay in ICU | 15 (3–44) | 25 (4–50) | 6 (1–24) | 0.0001 |
- SAPS2 | 42 (27–60) | 32 (22–46) | 61 (46–75) | < 0.0001 |
Nephrotoxic in ICU | ||||
- Aminoglycoside | 188 (25.4) | 115 (23.2) | 73 (42.9) | 0.0548 |
- Vancomycin | 41 (5.5) | 22 (4.4) | 19 (7.8) | 0.4011 |
- Contrast product | 74 (10) | 41 (8.3) | 33 (13.6) | 0.0331 |